Delving into the Latest Updates on WBD156 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

WBD156

Target

GLP-1R

Action

agonists

Mechanism

GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Obesity

Inactive Indication-

Originator Organization

Venn Biosciences Corp.

Active Organization

Wayne Biotechnology Limited

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评估 WBD156 胶囊在健康受试者及超重/肥胖受试者中的安全性和耐受性。次要目的：1.评估 WBD156 胶囊在健康受试者及超重/肥胖受试者中的药代动力学（PK）特征；2. 评估 WBD156 胶囊在健康受试者及超重/肥胖受试者中的药效动力学（PD）特征；3.评估食物对 WBD156 胶囊的药代动力学（PK）影响（仅 20 mg 组）；4.评估 WBD156胶囊在超重/肥胖受试者中的初步疗效；5. 初步评估 WBD156 胶囊在人体内的代谢情况。探索性目的：初步探索 WBD156 胶囊对按心率校正的 QT 间期（QTc）的影响。

[Translation]

Primary Objective: To evaluate the safety and tolerability of WBD156 Capsules in healthy subjects and overweight/obese subjects. Secondary Objectives: 1. To evaluate the pharmacokinetic (PK) characteristics of WBD156 Capsules in healthy subjects and overweight/obese subjects; 2. To evaluate the pharmacodynamic (PD) characteristics of WBD156 Capsules in healthy subjects and overweight/obese subjects; 3. To evaluate the effect of food on the pharmacokinetic (PK) of WBD156 Capsules (20 mg group only); 4. To evaluate the preliminary efficacy of WBD156 Capsules in overweight/obese subjects; 5. To preliminarily evaluate the metabolism of WBD156 Capsules in humans. Exploratory Objective: To preliminarily explore the effect of WBD156 Capsules on the QT interval corrected for heart rate (QTc).

Start Date21 Aug 2025

Sponsor / Collaborator

Wayne Biotechnology Limited

100 Clinical Results associated with WBD156

Login to view more data

100 Translational Medicine associated with WBD156

Login to view more data

100 Patents (Medical) associated with WBD156

Login to view more data

100 Deals associated with WBD156

Login to view more data